Stevanato Group (NYSE:STVN) Earns Outperform Rating from Wolfe Research

Stevanato Group (NYSE:STVN)‘s stock had its “outperform” rating reaffirmed by stock analysts at Wolfe Research in a report issued on Tuesday,Benzinga reports. They presently have a $21.00 target price on the stock.

A number of other analysts have also commented on the company. Jefferies Financial Group set a $17.50 price objective on Stevanato Group in a research report on Tuesday, February 10th. KeyCorp lowered their price objective on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating for the company in a research report on Thursday, March 5th. Weiss Ratings lowered Stevanato Group from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, March 11th. Morgan Stanley lowered their price objective on Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating for the company in a research report on Friday, March 6th. Finally, Citigroup lowered their price objective on Stevanato Group from $32.00 to $26.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Stevanato Group currently has an average rating of “Moderate Buy”.

Stevanato Group Price Performance

Shares of STVN stock opened at €18.86 on Tuesday. The stock has a 50-day moving average price of €16.08 and a 200 day moving average price of €17.88. The company has a quick ratio of 1.11, a current ratio of 1.63 and a debt-to-equity ratio of 0.21. The firm has a market cap of $5.71 billion, a price-to-earnings ratio of 31.97, a PEG ratio of 1.72 and a beta of 0.78. Stevanato Group has a 12 month low of €12.89 and a 12 month high of €28.00.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings data on Friday, May 8th. The company reported €0.11 EPS for the quarter, missing analysts’ consensus estimates of €0.12 by (€0.01). The firm had revenue of €273.57 million during the quarter. Stevanato Group had a return on equity of 10.27% and a net margin of 11.76%.The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period last year, the firm posted $0.10 EPS. Research analysts expect that Stevanato Group will post 0.68 EPS for the current year.

Hedge Funds Weigh In On Stevanato Group

Institutional investors have recently modified their holdings of the business. GW&K Investment Management LLC lifted its holdings in shares of Stevanato Group by 76.2% during the 4th quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock valued at $49,000 after purchasing an additional 1,055 shares in the last quarter. Fifth Third Bancorp lifted its holdings in shares of Stevanato Group by 22.6% during the 1st quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock valued at $58,000 after purchasing an additional 773 shares in the last quarter. State of Wyoming lifted its holdings in shares of Stevanato Group by 39,216.7% during the 2nd quarter. State of Wyoming now owns 2,359 shares of the company’s stock valued at $58,000 after purchasing an additional 2,353 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Stevanato Group during the 3rd quarter valued at about $68,000. Finally, Van Berkom & Associates Inc. lifted its holdings in shares of Stevanato Group by 50.6% during the 3rd quarter. Van Berkom & Associates Inc. now owns 3,615 shares of the company’s stock valued at $93,000 after purchasing an additional 1,215 shares in the last quarter.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.